At the news
? BULLISHIMPACT 7/10 8-K filed Aug 6, 2026 at 07:56 ET
Viatris Q2 2026 earnings beat consensus with adjusted EPS of $0.69 (15% above $0.60 est) and total revenue of $3.76B (+5% YoY, 2.4% above consensus). The company raised midpoints of all 2026 guidance metrics, revenue to $14.75B, adjusted EBITDA to $4.4B, adjusted EPS to $2.52, and free cash flow to $2.2B, while reducing gross leverage to 2.9x and returning $550M to shareholders. Material headwinds from the Nashik facility disruption ($100-150M H2 revenue impact) are partially offset by FDA approval of Gwyn Lo and the Tyrvaya sale.
- Q2 adjusted EPS $0.69 vs consensus $0.60 (+15% beat)
- Total revenue $3.76B vs consensus $3.67B (+2.4% beat); reported growth +5%, operational +4%
- Raised 2026 guidance midpoints: revenue $14.75B (from $14.70B), adj. EBITDA $4.40B (from $4.30B), adj. EPS $2.52 (from $2.40), FCF $2.20B (from $2.15B)
- Gross leverage ratio reduced to 2.9x; $900M debt repaid, refinanced with €650M notes
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access